Ignite Creation Date:
2025-12-26 @ 10:58 AM
Ignite Modification Date:
2025-12-29 @ 2:39 PM
Study NCT ID:
NCT04866706
Status:
COMPLETED
Last Update Posted:
2023-11-22
First Post:
2021-04-18
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Performance and Safety of Routine Cataract Surgery With Visiol
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'CASE_ONLY'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 100}, 'targetDuration': '3 Months', 'patientRegistry': True}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2022-01-27', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-04', 'completionDateStruct': {'date': '2023-10-27', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-11-21', 'studyFirstSubmitDate': '2021-04-18', 'studyFirstSubmitQcDate': '2021-04-26', 'lastUpdatePostDateStruct': {'date': '2023-11-22', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2021-04-30', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-12-09', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Corneal endothelial cells area', 'timeFrame': 'Change from pre-surgery Corneal endothelial cells area at Day 1, Day 7, Day 30, Day 90', 'description': 'The area (µm2) of corneal endothelial cells will be measured using a non-contact specular microscopy.'}, {'measure': 'Corneal endothelial cells density', 'timeFrame': 'Change from pre-surgery Corneal endothelial cells density at Day 1, Day 7, Day 30, Day 90', 'description': 'The density (cells/mm2) of corneal endothelial cells will be measured using a non-contact specular microscopy.'}, {'measure': 'Corneal endothelial cells regularity', 'timeFrame': 'Change from pre-surgery Corneal endothelial cells regularity at Day 1, Day 7, Day 30, Day 90', 'description': 'The regularity (variation of size) of corneal endothelial cells will be measured using a non-contact specular microscopy. In particular, the endothelial regularity will be assessed using the following classification described in ISO 11980:2012:37 0 = Regular endothelial mosaic;\n\n1. = Isolated difference in cell size;\n2. = Just noticeable variation in cell size or bumpiness of cell layer;\n3. = Easily detected difference in cell size or bumpiness of cell layer;\n4. = Noticeable cell layer bumpiness and loss of definition of cell borders.'}, {'measure': 'The presence of keratic precipitates', 'timeFrame': 'Change from pre-surgery presence of keratic precipitate at Day 1, Day 7, Day 30, Day 90', 'description': 'The presence (0 = No, 1 = Yes) of Keratic precipitate will be recorded'}, {'measure': 'A description of keratic precipitates type', 'timeFrame': 'Change from pre-surgery a description of keratic precipitates type at Day 1, Day 7, Day 30, Day 90', 'description': 'A description of keratic precipitates type will be recorded'}, {'measure': 'Central corneal thickness', 'timeFrame': 'Change from pre-surgery central corneal thickness at Day 1, Day 7, Day 30, Day 90', 'description': 'Central corneal thickness (micrometer) will be measured using non-contact specular microscopy'}, {'measure': 'Corneal oedema', 'timeFrame': 'Change from pre-surgery corneal oedema at Day 1, Day 7, Day 30, Day 90', 'description': 'Corneal oedema grading will be assessed using a specular microscopy. Gradings will be referred to location of oedema\n\n1. = Peripheral oedema\n2. = Central oedema\n3. = Generalised oedema'}, {'measure': 'Intra-ocular pressure', 'timeFrame': 'Change from pre-surgery intra-ocular pressure at Day 0 (surgery day), Day 1, Day 7, Day 30, Day 90', 'description': 'Intra-ocular pressure (mmHg) will be evaluated using a Goldmann applanation tonometry'}, {'measure': 'Incidence of intra-ocular pressure peak', 'timeFrame': 'Change from pre-surgery intra-ocular pressure peaks at Day 0 (surgery day), Day 1, Day 7, Day 30, Day 90', 'description': 'The incidence of intra-ocular pressure peaks (≥ 30 mmHg) will be recorded'}, {'measure': 'Anterior chamber inflammation cell', 'timeFrame': 'Change from pre-surgery anterior chamber inflammation cell at Day 1, Day 7, Day 30, Day 90', 'description': 'Anterior chamber inflammation will be assessed using slit lamp biomicroscopy (1 mm slit beam). It will be classified based on SUN grading Grade 0 = \\< 1 cell in field Grade 0.5 = 1-5 cells in field Grade 1 = 6-15 cells in field Grade 2 = 16-25 cells in field Grade 3 = 26-50 cells in field Grade 4 = over 50 cells in field'}, {'measure': 'Anterior chamber inflammation flare', 'timeFrame': 'Change from pre-surgery anterior chamber inflammation flare at Day 1, Day 7, Day 30, Day 90', 'description': 'Anterior chamber inflammation will be assessed using slit lamp biomicroscopy (1 mm slit beam). It will be classified based on SUN grading Grade 0 = no flare Grade 1 = faint Grade 2 = moderate (iris/ lens details clear) Grade 3 = marked (iris/ lens details hazy) Grade 4 = Intense (fibrin/ plastic aqueous)'}, {'measure': 'Best corrected visual acuity (BCVA)', 'timeFrame': 'Change from pre-surgery BCVA at Day 1, Day 7, Day 30, Day 90', 'description': 'BCVA will be evaluated using standard ETDRS logMAR chart'}, {'measure': 'Intra-surgery information for duration of intervention', 'timeFrame': 'During Surgery (Day 0)', 'description': 'duration of intervention (min)'}, {'measure': 'Intra-surgery information for use of finger grip', 'timeFrame': 'During Surgery (Day 0)', 'description': 'Use of finger grip (yes or no)'}, {'measure': 'Intra-surgery information for time needed to remove VISIOL', 'timeFrame': 'During Surgery (Day 0)', 'description': 'Time needed to remove VISIOL (min) counted from the time when intra-ocular lens was inserted until when the aspiration tip is removed'}, {'measure': 'Intra-surgery information for volume of VISIOL used', 'timeFrame': 'During Surgery (Day 0)', 'description': 'Total volume of VISIOL used (mL)'}, {'measure': 'Intra-surgery information for material of intra-ocular lens used', 'timeFrame': 'During Surgery (Day 0)', 'description': 'Material of intra-ocular lens used (acrylic or silicone)'}, {'measure': 'Intra-surgery information for power of intra-ocular lens used', 'timeFrame': 'During Surgery (Day 0)', 'description': 'Power (diopters) of intra-ocular lens used'}, {'measure': 'Intra-surgery information for incision size', 'timeFrame': 'During Surgery (Day 0)', 'description': 'Incision size (mm)'}, {'measure': 'Intra-surgery information for energetic parameter power or energy', 'timeFrame': 'During Surgery (Day 0)', 'description': 'Power or energy (% or mJ) during phacoemulsification and photolysis'}, {'measure': 'Intra-surgery information for time of phacoemulsification', 'timeFrame': 'During Surgery (Day 0)', 'description': 'Time (min) during phacoemulsification'}, {'measure': 'Intra-surgery information for vacuum', 'timeFrame': 'During Surgery (Day 0)', 'description': 'Vacuum (mmHg) during phacoemulsification'}, {'measure': "Investigator's subjective judgement", 'timeFrame': 'During Surgery (Day 0)', 'description': 'using a 4 point grading scale: ease of VISIOL injection, maintenance of the anterior chamber depth during the capsulorhexis and IOL implantation, ability to remain in the anterior chamber during phacoemulsification and photolysis, clarity of the substance, ease of capsulorhexis, ease of IOL implementation, ease of VISIOL removal and global impression on the product performance during the surgery. Grading scale will be assessed 0 = Not effective\n\n1. = slightly effective\n2. = moderately effective\n3. = very effective'}, {'measure': 'Global evaluation of the performance by the investigator', 'timeFrame': 'Surgery day (Day 0) and Day 90', 'description': 'Global evaluation of the performance of cataract surgery with VISIOL by the investigator 0 = no improvement\n\n1. = slight improvement\n2. = moderate improvement\n3. = great improvement'}, {'measure': 'Global evaluation of the performance by the patient', 'timeFrame': 'Surgery day (Day 0) and Day 90', 'description': 'Global evaluation of the performance of cataract surgery with VISIOL by the patient 0 = no improvement\n\n1. = slight improvement\n2. = moderate improvement\n3. = great improvement'}, {'measure': 'Adverse events (AE)', 'timeFrame': 'Pre-surgery, Surgery day (Day 0), Day 1, Day 7, Day 30, Day 90', 'description': 'including their incidence, intensity, seriousness, expectedness and causal relationship with the use of investigational device or study procedure'}], 'primaryOutcomes': [{'measure': 'Corneal endothelial cells density in percent', 'timeFrame': 'Change from pre-surgery Corneal endothelial cells density at Day 1, Day 7, Day 30, Day 90', 'description': 'The variation of corneal endothelial cells density (cells/mm2) as compared to baseline (pre-surgery) will be calculated (%)'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Following Cataract Surgery']}, 'descriptionModule': {'briefSummary': 'In this clinical investigation, the performance and safety of routine cataract surgery with VISIOL will be assessed'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Over 18 years cataract patients whom investigator routine considered to treat by surgery with Visiol before recruit to study', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Male or female aged 18 years and older;\n* Candidate for cataract surgery via phacoemulsification;\n* Ophthalmic surgeon's recommendation to use VISIOL prior to recruitment;\n* Eligible for the use of VISIOL as indicated in the instructions for use;\n* Written informed consent.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to any of VISIOL components;\n* Known pregnancy or breast feeding;\n* Participation in any other clinical research study within the last 90 days;\n* Patients with legally restricted autonomy, freedom of decision and action (e.g. those with measure of custody or judicial protection);\n* Incapacity to understand the informed consent and/or to comply with the Clinical Investigation Plan (CIP), per investigator's appreciation."}, 'identificationModule': {'nctId': 'NCT04866706', 'briefTitle': 'Performance and Safety of Routine Cataract Surgery With Visiol', 'organization': {'class': 'INDUSTRY', 'fullName': 'TRB Chemedica'}, 'officialTitle': 'Performance and Safety of Routine Cataract Surgery With Visiol', 'orgStudyIdInfo': {'id': 'SVS18-CT-1901'}}, 'armsInterventionsModule': {'interventions': [{'name': 'Visiol', 'type': 'DEVICE', 'otherNames': ['Sodium hyaluronate'], 'description': 'VISIOL is a 2.0% (m/v) SH viscoelastic solution used for ocular surgery.'}]}, 'contactsLocationsModule': {'locations': [{'zip': '10400', 'city': 'Bangkok', 'country': 'Thailand', 'facility': 'Rajavithi Hospital', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'TRB Chemedica', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}